Thomson Reuters BioWorld

BioWorld delivers actionable intelligence on the most innovative drug development science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld reports the breaking news - and provides key perspective - on hundreds of medicines in development, the companies behind those therapeutic candidates, the business development transactions that evolve the market, and the regulatory hurdles that both challenge and guard the process.